Fig. 1: CTC isolation platforms comparison.
From: Detection and prognostic role of heterogeneous populations of melanoma circulating tumour cells
a Comparison of the Parsortix (Angle plc), ClearCell FX1 (Biolidics) (LP: low purity and HP: high purity programmes) and the Slanted spiral microfluidics platforms, on their recovery rates of the melanoma cell lines A2058 or SK-MEL-5 (indicated as bars: left y-axis) and total WBC counts (indicated in green as mean ± SD: right y-axis). b WBC counts in CTC enriched samples, from 10 patients with metastatic melanoma, using the Parsortix (range: 965–12831) and ClearCell systems (LP mode, range: 4925–17732). c and d Expression levels of MLANA, TYR, MAGEA3, ABCB5, and PAX3 assessed by RT-PCR in matched CTC fractions enriched by c Parsortix and d ClearCell platforms. Each heatmap squares represents the expression levels for each gene and a given sample, shown by reciprocal Ct values. The 18S rRNA gene was used as an endogenous control. The CTC counts obtained by multimarker immunostaining for each matched CTC fraction derived from the same patient are indicated. NA data not available.
